Short answer: High-value pharma (specialty drugs, biologics, hi-tech medicines) is not a labor-cost race — it is a race of certification and trust. Singapore is expensive but owns an internationally recognised ecosystem (PIC/S GMP, an accredited drug regulator) that eases entry into demanding markets; Vietnam offers lower costs, a 100-million domestic market and policies attracting pharma investment, but a plant targeting strictly regulated export markets must be built to international standards from the design stage. This article works through Vietnam’s legal framework (as of 18 October 2026) against Singapore’s at a high level.
1. Four Decision Layers for High-Value Pharma
Layer 1 — GMP standards and exportability: high-value drugs only sell into the US, EU and Japan when the plant meets GMP recognised by their authorities (FDA, EMA) or at minimum PIC/S GMP. Building a PIC/S-GMP plant in Vietnam is entirely feasible — several have done it — but the investment and quality-system operating costs run materially higher than a domestic-standard-only plant. Singapore: most large plants have long operated inside the PIC/S ecosystem.
Layer 2 — Intellectual property and data protection: high-value pharma lives on exclusivity. Vietnam protects pharma patents under the IP Law; the practical issues are time and enforcement: patent prosecution takes years, and fighting counterfeits needs market surveillance. Singapore’s IP system is rated more effectively enforced in the region. For on-patent drugs, wherever the plant sits, protecting formula and process secrets must be costed in.
Layer 3 — Scientific talent: high-value pharma needs pharmacists, biotech engineers and QA/QC specialists — not general labor. Singapore has ready scientific talent; Vietnam is developing, but hiring internationally-qualified QA/QC remains a challenge — many plants bring foreign specialists in for the first 2–3 years.
Layer 4 — Destination markets: if the target is Vietnam’s domestic market and ASEAN — locate in Vietnam, close to the market, lower cost. If the target is the US/EU/Japan — the question is where the plant reaches certification faster and cheaper over its lifecycle, not the initial construction cost.
2. Vietnam’s Legal Framework for a Pharma Plant
- Investment: The Law on Investment No. 143/2025/QH15 (effective 1 March 2026) + Decree No. 96/2026/ND-CP — IRC issuance. Pharma manufacturing, especially hi-tech pharma, is an encouraged sector and may receive location- and sector-based incentives.
- Pharma licensing: the Law on Pharmacy (2016, as amended) governs drug-manufacturing conditions: the plant must meet GMP, have a professionally responsible pharmacist and a quality management system. This is the most important licence layer — the IRC is necessary but not sufficient; without the manufacturing eligibility licence the plant cannot operate.
- Marketing authorisation: each drug product manufactured must obtain a marketing authorisation before sale — technical dossier review (quality, safety, efficacy) takes months to years depending on drug type.
- Land: The Land Law No. 31/2024/QH15 (effective 1 August 2024) — land lease inside industrial parks; Decree No. 35/2022/ND-CP. Pharma plants need controlled environments (cleanrooms) and purified-water systems (PW/WFI) — higher infrastructure demands than ordinary plants.
- Environment: The Law on Environmental Protection No. 72/2020/QH14 — environmental impact assessment / environmental licence; pharma wastewater containing active ingredients needs dedicated treatment.
- Labor: the 2019 Labor Code; Decree No. 219/2025/ND-CP (effective 7 August 2025) for foreign specialists (QA/QC, technology transfer).
- Tax: 20% CIT + incentives (hi-tech pharma may qualify); the global minimum tax (Resolution No. 107/2023/QH15) if the group exceeds the threshold.
3. Layer-by-Layer Comparison
| Layer | Vietnam (current framework) | Singapore (high-level framework) |
|---|---|---|
| GMP standards | Law on Pharmacy requires GMP; PIC/S needs extra investment | Established PIC/S ecosystem |
| Manufacturing licence | Pharma manufacturing eligibility licence (Law on Pharmacy) + IRC | Own pharma licensing framework |
| Marketing authorisation | Technical dossier review per product | Registration to international standards |
| Pharma IP | Patent protection under the IP Law | Highly rated IP enforcement |
| Scientific talent | Developing; foreign specialists needed initially | Ready scientific talent pool |
Singapore’s framework is high-level only; details to be checked by local counsel.
4. Worked Scenario: High-Value Generics for ASEAN
Suppose you make high-value generics (oncology, autoimmune), selling in Vietnam and exporting to ASEAN:
- Step 1: Set the GMP target: domestic GMP suffices for Vietnam; but for demanding export markets later, designing to PIC/S from day one is cheaper than upgrading afterwards.
- Step 2: For Vietnam: IRC (check hi-tech pharma incentive eligibility), pharma manufacturing eligibility licence, marketing authorisation per product, park land (cleanroom infrastructure, purified water), EIA for pharma wastewater.
- Step 3: Plan QA/QC staffing: domestic hires + foreign specialists (work permits under Decree 219/2025) for the first 2–3 transfer years.
- Step 4: Compare 10-year lifecycle cost (construction + quality-system operation + multi-market authorisations) between the two options — not construction cost alone.
5. First-30-Days Checklist
- Define destination markets and the matching GMP standard (domestic / ASEAN / US-EU-Japan).
- Map pharma manufacturing licensing and marketing authorisation under the current Law on Pharmacy.
- Assess QA/QC talent: domestic hiring vs bringing specialists in.
- Survey parks meeting cleanroom, purified-water and pharma-wastewater demands.
- Engage local counsel in Singapore to check pharma licensing and R&D/manufacturing incentives.
6. Sequencing the Two Licences: A Timeline Illustration
A common planning error is treating the IRC and the pharma manufacturing licence as sequential paperwork. In practice, the manufacturing-eligibility dossier — GMP design documents, cleanroom qualification protocols, the appointment of the professionally responsible pharmacist — is built on top of the same technical drawings as the construction. Think of the project as three parallel tracks rather than a relay:
Track 1 — construction and cleanroom build-out: the visible part of the project.
Track 2 — GMP qualification: validation protocols, purified-water system qualification and the quality management system are designed alongside construction, not after it — because upgrading a cleanroom once built costs more than designing it to the target standard the first time. The GMP target (domestic vs PIC/S) must be fixed before breaking ground.
Track 3 — product authorisation: the marketing-authorisation dossier for the lead product — quality, safety, efficacy — starts during construction, not after the ribbon-cutting. Technical review takes months, and a finished plant waiting for its first product’s authorisation is capital standing idle.
The third constraint is staffing: the foreign QA/QC specialists who must witness process validation need their work permits under Decree 219/2025 processed early enough to be on site when validation begins.
A plant that reaches “qualified plant plus authorised first product” half a year earlier starts earning half a year earlier — and in high-value pharma, that earlier revenue is typically worth more than the entire construction-cost difference between two countries. That is why the location decision belongs to the certification race, not the labour-cost race.
This article is for general reference only and does not replace legal advice for your specific case. Details of Singaporean law should be checked by local counsel before deciding.
Frequently Asked Questions
1. What licences does a pharma plant in Vietnam need?
Two layers: (1) the IRC under the Law on Investment No. 143/2025/QH15 for the investment project; (2) the pharma manufacturing eligibility licence under the Law on Pharmacy (GMP-compliant plant, professionally responsible pharmacist, quality management system). Each drug product must also obtain a marketing authorisation before sale. Missing any layer, the plant cannot operate lawfully.
2. How hard is it to reach PIC/S GMP in Vietnam?
Feasible but demanding: cleanroom design, purified-water systems, quality-control processes and an internationally trained QA/QC team. Costs run materially higher than a domestic-standard plant. If the US/EU/Japan are the targets, building to international standards from day one is usually cheaper than upgrading later.
3. How does pharma patent protection work in practice in Vietnam?
Vietnam’s IP Law protects pharma patents (20-year term). The practical challenges are prosecution time (often many years) and enforcement effectiveness against infringement. Businesses should layer protection: patents, trade secrets (formulas, processes) and proactive market surveillance.
4. Why do many firms still choose Singapore despite the cost?
Because in high-value pharma, “cost” is not labor — it is time-to-market and quality risk. A ready PIC/S ecosystem, deep scientific talent and a highly rated IP system shorten certification timelines and cut compliance risk — for high-value drugs, each month of earlier market entry is worth far more than operating-cost differences.
5. Can we put R&D in Singapore and manufacturing in Vietnam?
This is a common model: R&D and IP registration in Singapore (leveraging the science and IP ecosystem), manufacturing in Vietnam (leveraging cost and market). But it demands tight technology-transfer governance, confidentiality agreements and transfer-pricing compliant with both countries’ tax rules.
This article has been quality-reviewed by the FLAW AI Legal Council
